Award Data

There is an increasing demand for systems with more autonomous operations interacting with other autonomous and human-based systems. What is needed is an architecture bundled with developer tools for the creation of intelligent real-time control systems that marry the talents of modern control theory, software technology, sensory processing, and semantic knowledge representations. It would be a st ...

DESCRIPTION (provided by applicant): This is a Phase II SBIR proposal to develop a new therapy for the treatment of asthma. The desired outcome will be the identification of a therapeutic candidate to replace theophylline, a non-selective adenosine receptor antagonist that is effective in treating asthma, but limited by side effects, primarily insomnia, mediated by blockade the A1AR in the brain. ...

DESCRIPTION (provided by applicant): This is a phase I STTR application to study the efficacy of selective adenosine A2A receptor (A2AR) agonists developed in the laboratories of Adenosine Therapeutics (ATL) in models of Gram-positive bacterial sepsis which will be conducted in the University of Virginia (UVA) laboratories of Dr. Michael Scheld, an expert in the field of infectious disease. Sepsis ...

DESCRIPTION (provided by applicant): This is the first revision of a phase I STTR proposal to develop new therapies for the treatment of rheumatoid arthritis (RA). It is collaboration between a biotechnology company, Adenosine Therapeutics, LLC (ATL) based in Charlottesville, VA, and the University of Virginia laboratory of Dr. Donald L. Kimpel, a Rheumatologist experienced in the study of RA. Hum ...

DESCRIPTION (provided by applicant): ATL146e is a synthetic small molecule developed by Adenosine Therapeutics, LLC (ATL) that acts as a selective agonist of the adenosine A2A receptor. ATL146e, sterile solution for intravenous (i.v.) bolus injection, is currently in Phase III of clinical development for use as a coronary vasodilator in pharmacodynamic stress imaging. ATL146e, when administered pa ...

DESCRIPTION (provided by applicant): Non-Hodgkin's Lymphoma (NHL) is characterized by an indolent clinical course with a median survival of 6- 10 years. The incidence of NHL in the US increases by about 2.5% per year. Clearly, there is a national need for improved therapies for this malignancy. Idiotype-based clinical trials for minimal residual disease of follicular NHL have shown increased disea ...

DESCRIPTION (provided by applicant): We will develop a disposable, affinity-based capillary tube [AffiTip] that is capable of removing 99% of the interfering bulk protein from < 5 :L of undiluted plasma within 2 minutes for use prior to analysis for biomarkers [specific compounds that link mechanism of action and clinical effectiveness]. The product ultimately will be introduced at a sale price [p ...

DESCRIPTION (provided by applicant): The goal of this program is to develop novel inhibitors of human sphingosine kinase (SK) that are effective as therapeutic agents. Because of its critical role in sphingolipid metabolism, we have focused on SK as an innovative molecular target for the development of new drugs for the treatment of Inflammatory Bowel Diseases (IBDs). Sphingolipids are being incre ...

DESCRIPTION (provided by applicant): Principal Investigator/Program Director: French, Kevin J. Abstract: The long-term goal of this program is to develop inhibitors of human sphingosine kinase (SK) that are effective as therapeutic agents. Because of its critical role in sphingolipid metabolism, we have focused on SK as an innovative molecular target for the development of new drugs for the treatm ...

DESCRIPTION (provided by applicant): In spite of advances in medical and surgical treatment, there are at any one time estimated to be some 350,000 individuals in this country whose seizures occur without warning and result in some combination of disordered thinking, impaired consciousness, or loss of motor control. Epileptologists and patients alike have long understood the magnitude of this prob ...